Latest

Pediatric Pulmonary Arterial Hypertension Drug Approved by FDA

Pediatric Pulmonary Arterial Hypertension Drug Approved by FDA

The first FDA-approved drug for pediatric pulmonary arterial hypertension will be available in 32 mg tablets for oral suspension.

Safety, Efficacy of Treprostinil Delivery System for PAH Examined

Safety, Efficacy of Treprostinil Delivery System for PAH Examined

Researchers were able to successfully use a fully implantable delivery system for treprostinil for adult patients with pulmonary arterial hypertension.

Using Hemodynamic Marker Ratio to Predict Outcomes in Pulmonary Hypertension

Using Hemodynamic Marker Ratio to Predict Outcomes in Pulmonary Hypertension

A retrospective analysis demonstrated that the ratio of left to right ventricular end-diastolic pressures can predict outcomes in patients with PH.

ACR Imaging Criteria for Suspected Pulmonary Hypertension

ACR Imaging Criteria for Suspected Pulmonary Hypertension

New criteria by the American College of Radiology detail appropriateness of various imaging techniques for suspected pulmonary hypertension.

Predicting Survival in IPF With CT-Measured Pulmonary Artery: Aorta Ratio

Predicting Survival in IPF With CT-Measured Pulmonary Artery: Aorta Ratio

Computed tomography-derived pulmonary artery-to-aorta ratio can predict pulmonary artery pressure and survival in patients with idiopathic pulmonary fibrosis.

Biomarkers of PAH Risk in Patients With SLE

Biomarkers of PAH Risk in Patients With SLE

Meta-analysis supports anti-RNP and anti-Sm antibodies as serological biomarkers of PAH risk in patients with SLE.

MRIs Can Predict Outcomes in Pulmonary Arterial Hypertension

MRIs Can Predict Outcomes in Pulmonary Arterial Hypertension

MRI measures can predict outcomes in pulmonary arterial hypertension.

Pulmonary Arterial Hypertension: Expert Interview

Pulmonary Arterial Hypertension: Expert Interview

Pulmonary and genetics experts James E. Loyd, MD, and Wendy Chung, MD, PhD, offer insight into the role of genetics in pulmonary arterial hypertension.

Safety and Efficacy of Combination Treatment for CTD-PAH

Safety and Efficacy of Combination Treatment for CTD-PAH

Combination therapy with ambrisentan and tadalafil may improve response in patients with connective tissue disease-associated pulmonary arterial hypertension.

Sign Up for Free e-newsletters